These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31000106)

  • 1. Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome.
    Cheung CC; Mellor G; Deyell MW; Ensam B; Batchvarov V; Papadakis M; Roberts JD; Leather R; Sanatani S; Healey JS; Chauhan VS; Birnie DH; Champagne J; Angaran P; Klein GJ; Yee R; Simpson CS; Talajic M; Gardner M; Yeung-Lai-Wah JA; Chakrabarti S; Laksman ZW; Sharma S; Behr ER; Krahn AD
    JACC Clin Electrophysiol; 2019 Apr; 5(4):504-512. PubMed ID: 31000106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-channel blocker challenge in the familial screening of Brugada syndrome: Safety and predictors of positivity.
    Therasse D; Sacher F; Petit B; Babuty D; Mabo P; Martins R; Jesel L; Maury P; Pasquie JL; Mansourati J; Dupuis JM; Kyndt F; Thollet A; Guyomarch B; Barc J; Schott JJ; Le Marec H; Redon R; Probst V; Gourraud JB
    Heart Rhythm; 2017 Oct; 14(10):1442-1448. PubMed ID: 28666944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular arrhythmia during ajmaline challenge for the Brugada syndrome.
    Dobbels B; De Cleen D; Ector J
    Europace; 2016 Oct; 18(10):1501-1506. PubMed ID: 26941343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Brugada Syndrome With a Sodium-Channel-Blocker Test: Who Should Be Tested? Who Should Not?
    Viskin S; Chorin E; Rosso R; Amin AS; Wilde AA
    Circulation; 2024 Aug; 150(8):642-650. PubMed ID: 39159224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Peak to T-End Interval for Prediction of Positive Response to Ajmaline Challenge Test in Suspected Brugada Syndrome Patients.
    Thapanasuta M; Chokesuwattanaskul R; Leelapatana P; Rungpradubvong V; Prechawat S
    Med Sci (Basel); 2022 Dec; 10(4):. PubMed ID: 36548004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procainamide infusion in the evaluation of unexplained cardiac arrest: from the Cardiac Arrest Survivors with Preserved Ejection Fraction Registry (CASPER).
    Somani R; Krahn AD; Healey JS; Chauhan VS; Birnie DH; Champagne J; Sanatani S; Angaran P; Gow RM; Chakrabarti S; Gerull B; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Klein GJ; Gollob MH; Talajic M; Gardner M; Simpson CS
    Heart Rhythm; 2014 Jun; 11(6):1047-54. PubMed ID: 24657429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy.
    Papadakis M; Papatheodorou E; Mellor G; Raju H; Bastiaenen R; Wijeyeratne Y; Wasim S; Ensam B; Finocchiaro G; Gray B; Malhotra A; D'Silva A; Edwards N; Cole D; Attard V; Batchvarov VN; Tome-Esteban M; Homfray T; Sheppard MN; Sharma S; Behr ER
    J Am Coll Cardiol; 2018 Mar; 71(11):1204-1214. PubMed ID: 29544603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.
    Maury P; Audoubert M; Cintas P; Rollin A; Duparc A; Mondoly P; Chiriac AM; Acket B; Zhao X; Pasquié JL; Cardin C; Delay M; Sadron M; Carrié D; Galinier M; Davy JM; Arne-Bès MC; Raczka F
    Heart Rhythm; 2014 Oct; 11(10):1721-7. PubMed ID: 25016148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
    Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C
    Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Report of Brugada Syndrome Presenting with Cardiac Arrest Triggered by Verapamil Intoxication.
    Yakut K; Erdoğan İ; Varan B; Atar İ
    Balkan Med J; 2017 Dec; 34(6):576-579. PubMed ID: 29215340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia.
    Hasdemir C; Payzin S; Kocabas U; Sahin H; Yildirim N; Alp A; Aydin M; Pfeiffer R; Burashnikov E; Wu Y; Antzelevitch C
    Heart Rhythm; 2015 Jul; 12(7):1584-94. PubMed ID: 25998140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ST-Elevation Magnitude Correlates With Right Ventricular Outflow Tract Conduction Delay in Type I Brugada ECG.
    Leong KMW; Ng FS; Yao C; Roney C; Taraborrelli P; Linton NWF; Whinnett ZI; Lefroy DC; Davies DW; Boon Lim P; Harding SE; Peters NS; Kanagaratnam P; Varnava AM
    Circ Arrhythm Electrophysiol; 2017 Oct; 10(10):. PubMed ID: 29038102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome.
    Ueoka A; Morita H; Watanabe A; Morimoto Y; Kawada S; Tachibana M; Miyamoto M; Nakagawa K; Nishii N; Ito H
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29748178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of intracardiac electrogram with surface electrocardiogram in Brugada syndrome patients.
    Probst V; Sacher F; Derval N; Gourraud JB; Mabo P; Medkour F; Le Marec H; Gill J
    Europace; 2014 Jun; 16(6):908-13. PubMed ID: 24068444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores.
    Tadros R; Tan HL; ; El Mathari S; Kors JA; Postema PG; Lahrouchi N; Beekman L; Radivojkov-Blagojevic M; Amin AS; Meitinger T; Tanck MW; Wilde AA; Bezzina CR
    Eur Heart J; 2019 Oct; 40(37):3097-3107. PubMed ID: 31504448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges.
    Veltmann C; Wolpert C; Sacher F; Mabo P; Schimpf R; Streitner F; Brade J; Kyndt F; Kuschyk J; Le Marec H; Borggrefe M; Probst V
    Europace; 2009 Oct; 11(10):1345-52. PubMed ID: 19589796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and electrocardiographic predictors of positive response to the intravenous sodium channel blockers in patients suspected of the Brugada syndrome.
    Shahrzad S; Khoramshahi M; Aslani A; Fazelifar AF; Haghjoo M
    Int J Cardiol; 2013 May; 165(2):285-90. PubMed ID: 21917337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal ECG changes in pediatric patients undergoing procainamide challenge.
    Jordan CP; Berul CI; Moak JP; Greene EA
    Pacing Clin Electrophysiol; 2014 Sep; 37(9):1106-10. PubMed ID: 24831303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations.
    Hong K; Brugada J; Oliva A; Berruezo-Sanchez A; Potenza D; Pollevick GD; Guerchicoff A; Matsuo K; Burashnikov E; Dumaine R; Towbin JA; Nesterenko V; Brugada P; Antzelevitch C; Brugada R
    Circulation; 2004 Nov; 110(19):3023-7. PubMed ID: 15520322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome.
    Wolpert C; Echternach C; Veltmann C; Antzelevitch C; Thomas GP; Spehl S; Streitner F; Kuschyk J; Schimpf R; Haase KK; Borggrefe M
    Heart Rhythm; 2005 Mar; 2(3):254-60. PubMed ID: 15851314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.